United Therapeutics Corp. SEC Filings

Causey Christopher, a director of United Therapeutics (UTHR), reported insider transactions on 09/24/2025. He exercised a stock option to acquire 1,000 shares at an exercise price of $119.76 and simultaneously sold 1,000 shares at $440 per share. After the transactions, the filing reports 4,865 shares beneficially owned directly and 9,320 shares represented by derivative holdings.

Rothblatt Martine A, Chairperson & CEO of United Therapeutics (UTHR), reported exercises and sales of company stock options under a pre-arranged 10b5-1 trading plan entered May 2, 2025. On 09/23/2025 and 09/24/2025 she exercised a total of 8,000 options at an exercise price of $120.26 each, and sold shares in multiple trades at weighted-average prices ranging from about $416.51 to $436.84 depending on the tranche. Following the reported transactions she directly owns smaller blocks of shares and continues to have significant indirect holdings through family trusts and spouse-controlled accounts totaling the amounts listed on the form. The option tranche referenced totals 294,000 options expiring March 15, 2026, and the 10b5-1 plan runs until that tranche is exhausted or December 31, 2025.

UNITED THERAPEUTICS (UTHR) Form 144 filing: An insider, Martine Rothblatt, notified the sale of 4,000 common shares through TD Securities with an approximate aggregate market value of $1,723,659, and the filing lists the issuer's outstanding common shares as 45,230,000. The securities reported were originally acquired on 03/15/2016 as part of an executive deferred compensation arrangement totaling 294,000 shares, with payment made via exercised vested options. The filing also discloses multiple prior open-market sales by the same person during September 2025, totaling 52,000 shares across listed dates and generating the gross proceeds shown per trade. The filer certifies no undisclosed material adverse information.

The filing is a Form 144 notice for proposed sale of 1,000 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on 09/24/2025 with an aggregate market value of $440,000.00. The securities were acquired and paid for on 09/24/2025 by stock option exercise. The filing shows 45,226,262 shares outstanding for the issuer. The notice discloses prior sales by an identified seller of 3,000 shares on 09/02/2025 for gross proceeds of $1,269,630.00. The signer represents they have no material nonpublic information regarding the issuer.

Form 144 filed for United Therapeutics (UTHR) reporting proposed and recent insider sales by Martine Rothblatt. The notice lists a proposed sale of 4,000 common shares through TD Securities on 09/24/2025 with an aggregate market value of $1,736,408.50 and shows the company has 45,230,000 shares outstanding. The filer records the original acquisition of the securities on 03/15/2016 under an executive deferred compensation arrangement, noting 294,000 shares acquired and that payment involved exercised options and common shares. The filing also discloses multiple sales by Martine Rothblatt from 09/09/2025 through 09/23/2025 totaling 48,000 common shares with gross proceeds listed per trade.

United Therapeutics insider activity: Michael Benkowitz, President and COO, exercised stock options and sold the resulting shares on 09/22/2025 under a Rule 10b5-1 trading plan entered into June 3, 2025. The filing shows exercise of 14,625 options at $135.42 and sale of the resulting 14,625 shares at $416.3535, and exercise of 7,875 options at $146.03 with sale of those 7,875 shares at $416.3535. Following the sales, the reported beneficial ownership from the two trusts tied to the reporting person shows 0 shares for the sold lots. The transactions were executed through trusts of which the reporting person is a beneficiary or trustee, and were signed under power of attorney on 09/23/2025.

United Therapeutics (UTHR) Form 144 filing: This notice reports proposed and recent sales of the issuer's common stock by Martine Rothblatt. The filing shows a proposed sale of 4,000 shares through TD Securities on 09/23/2025 with an aggregate market value of $1,617,665.13. It discloses the securities were originally acquired on 03/15/2016 as executive deferred compensation and converted via vested options, totaling 294,000 shares acquired on that date. The filer also reported 44,000 shares sold across ten transactions from 09/09/2025 to 09/22/2025. The company had 45,230,000 shares outstanding per the form.

United Therapeutics (UTHR) Form 144 notice: The filer disclosed a proposed sale of 4,000 common shares to be executed on 09/22/2025 through TD Securities (USA) LLC, with an aggregate market value of $1,669,212.50. The filing shows 45,230,000 shares outstanding. Acquisition details state the shares were originally acquired on 03/15/2016 as part of executive deferred compensation from Martine Rothblatt, totaling 294,000 shares under that grant and paid via exercised vested options. The filing also lists nine sales by Martine Rothblatt from 09/09/2025 to 09/19/2025 totaling 40,000 shares, with per-day gross proceeds reported for each sale.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), reported option exercises and stock sales executed under a pre-arranged 10b5-1 plan. On 09/19/2025 and 09/22/2025 she exercised stock options with an exercise price of $120.26, acquiring 4,000 shares on each date and immediately selling the same or part of those shares in multiple trades at weighted-average prices reported as $411.0775, $416.7188 and $417.8875. The filing shows direct beneficial ownership of 4,130 shares and indirect holdings through spouse and family trusts totaling reported blocks of 166, 324,518, 258,117, 45,596 and 15,962 shares. The transactions were carried out pursuant to a 10b5-1 plan established May 2, 2025, which continues until tranche exhaustion (294,000 options expiring 03/15/2026) or December 31, 2025.